Bioventus

Bioventus, Inc. is a medical technology company, which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. It operates through the following business segments: Active Healing Therapies-U.S, Active Healing Therapies-International, Surgical and BMP. The Active Healing Therapies-U.S and International offers two types of non-surgical products which are non-invasive exogen system for long bone stimulation for fracture healing and hyaluronic acid, or HA, viscosupplementation therapies for osteoarthritis pain relief. The Surgical segment offers a portfolio of advanced bone graft substitutes. The BMP segment comprises proprietary next-generation bone morphogenetic protein, or BMP. The company was founded on November 23, 2011 and is headquartered in Durham, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bioventus reports Q4 revenue decline, focuses on operational efficiency

Bioventus faced revenue challenges in Q4 2022 but demonstrated strength in key segments like Surgical Solutions and international growth.
Actions taken to enhance earnings and financial stability show a commitment to improving performance and regaining investor confidence.
Challenges around revenue decline, gross margin impact, and uncertainty require strategic focus on debt management and operational efficiency.

Bioventus reports Q1 revenue growth, addresses market challenges and opportunities

Bioventus delivered solid Q1 performance with revenue growth and improved EBITDA.
Challenges in the HA market and potential divestitures were key discussion points.
Opportunities lie in revenue growth strategies, cost management, and portfolio optimization.
Overall, Bioventus aims to leverage strengths for sustained growth and profitability.

Bioventus reports Q2 growth, eyes talent acquisition for future

Bioventus showcased financial achievements in Q2 2023, with a focus on improving execution, profitability, and reducing leverage.
Despite revenue decline, the company's adjusted EBITDA increased, driven by strong volume growth in pain treatments and international segment expansion.
Management's confidence in the product portfolio, growth prospects, and talent acquisition bodes well for Bioventus's future performance and strategic direction.

Bioventus reports Q3 resilience, eyes growth in international markets

Bioventus showcased resilience with strong performance in key segments despite revenue decline.
The company's strategic focus on growth drivers and international expansion bodes well for future prospects.
Challenges in certain segments are being addressed with plans for improvement and return to growth.
2024 plans emphasize investments in sales, R&D, and portfolio optimization for sustained growth.

Bioventus reports robust Q4 earnings, sets ambitious goals for 2024

Bioventus delivered strong financial performance in Q4 2023 and outlined ambitious goals for 2024.
The company's focus on revenue growth, operational efficiency, and cash flow improvement reflects a strategic approach to value creation.
While facing debt leverage challenges, Bioventus aims to leverage its strengths and opportunities to drive sustainable growth.
Investors should monitor Bioventus' progress in executing its 2024 priorities and achieving the set financial targets.

Bioventus excels in Q1 2024, focuses on growth and profitability

Bioventus demonstrated robust performance in Q1 2024, driven by revenue growth and margin improvement.
While facing challenges in international growth and operational areas, the company remains optimistic about long-term prospects.
Management's strategic priorities and financial achievements position Bioventus well for future growth and profitability.
Analyst inquiries highlighted key areas for improvement and strategic focus for Bioventus moving forward.

Bioventus excels in Q2 2024, focuses on core growth

Bioventus reported a strong Q2 2024 with revenue growth, improved profitability, and strategic divestment decision
The company aims to drive double-digit revenue and EBITDA growth for the rest of 2024 and into 2025
Despite challenges in Restorative Therapies sales, Bioventus remains focused on core segments for growth
Enhanced financial guidance and operational efficiency position Bioventus for continued success and expansion

Bioventus posts strong Q3 results, eyes growth in medical solutions

Bioventus (BVS) reported robust Q3 results with revenue growth, improved EBITDA, and positive cash flow, reflecting operational strength and financial stability.
Strategic initiatives like the sale of the rehabilitation business demonstrate a focus on optimizing the portfolio and enhancing shareholder value.
While challenges exist in Q4 growth and business transitions, Bioventus remains well-positioned to leverage opportunities in high-demand medical solutions and international markets.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Boston, Massachusetts--(Newsfile Corp. - January 18, 2023) - Block & Leviton is investigating Bioventus, Inc. (NASDAQ: BVS) for potential securities law violations. Investors who have lost money in their Bioventus, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/bvs.What is this all about?Before the market opened on November 8, 2022, Bioventus, Inc.

Bioventus Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Bioventus To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - January 13, 2023) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS).If you suffered losses exceeding $50,000 investing in Bioventus stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/BVS.

Bioventus Investor Alert

NEW YORK , Jan. 12, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS) and certain officers and directors. The class action, filed in the United States District Court for the Middle District of North Carolina, and docketed under 23-cv-00032, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Bioventus Class A common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about February 11, 2021 (the "IPO" or "Offering"); and/or (b) Bioventus securities between February 11, 2021 and November 21, 2022, both dates inclusive (the "Class Period").

Pomerantz Law Firm Announces the Filing of a Class Action Against Bioventus Inc. and Certain Officers and Directors - BVS

DURHAM, N.C., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Ken Reali, chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 5:15 p.m. PT (8:15 p.m. ET).

Bioventus to Present at the 41st Annual J.P. Morgan Healthcare Conference

NEW YORK , Dec. 26, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS).  Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bioventus Inc. - BVS

New York, New York--(Newsfile Corp. - December 17, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Bioventus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bioventus Inc. - BVS

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Bioventus To Contact Him Directly To Discuss Their Options NEW YORK , Dec. 13, 2022 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS). If you suffered losses exceeding $50,000 investing in Bioventus stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext.

BIOVENTUS SHAREHOLDER ACTION REMINDER

NEW YORK , Dec. 7, 2022 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS). Investors who purchased Bioventus securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/bvs.

Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Bioventus Inc. (BVS)

NEW YORK , Nov. 30, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Bioventus Inc. (NASDAQ: BVS) resulting from allegations that Bioventus may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Bioventus securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

BVS BREAKING NEWS: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Bioventus Inc. Investors to Inquire About Securities Class Action Investigation - BVS

LOS ANGELES--( BUSINESS WIRE )--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Bioventus Inc. (“Bioventus” or the “Company”) (NASDAQ: BVS) investors concerning the Company's possible violations of the federal securities laws.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Bioventus Inc. (BVS) on Behalf of Investors

BENSALEM, Pa.--( BUSINESS WIRE )--Law Offices of Howard G. Smith announces an investigation on behalf of Bioventus Inc. (“Bioventus” or the “Company”) (NASDAQ: BVS) investors concerning the Company's possible violations of federal securities laws.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Bioventus Inc. (BVS) on Behalf of Investors

LOS ANGELES--( BUSINESS WIRE )--The Law Offices of Frank R. Cruz announces an investigation of Bioventus Inc. (“Bioventus” or the “Company”) (NASDAQ: BVS) on behalf of investors concerning the Company's possible violations of federal securities laws.

The Law Offices of Frank R. Cruz Announces Investigation of Bioventus Inc. (BVS) on Behalf of Investors

NEW YORK--( BUSINESS WIRE )--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Bioventus Inc. (NASDAQ: BVS) resulting from allegations that Bioventus may have issued materially misleading business information to the investing public.

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Bioventus Inc. Investors to Inquire About Securities Class Action Investigation – BVS

DURHAM, N.C., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today amended its previously announced financial results for the three and nine months ended October 1, 2022.

Bioventus Issues Revised Third Quarter Results; Updates Full-Year 2022 Financial Guidance

DURHAM, N.C., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today the Company has filed a Form 12b-25, Notification of Late Filing for its Quarterly Report on Form 10-Q for the period ended October 1, 2022.

Bioventus Files for Extension to File Form 10-Q for the Period Ended October 1, 2022

Los Angeles, California--(Newsfile Corp. - November 14, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Bioventus Inc. ("Bioventus" or "the Company") (NASDAQ: BVS) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Bioventus Inc. and Encourages Investors with Losses to Contact the Firm

Bioventus Inc. (NASDAQ:BVS ) Q3 2022 Earnings Conference Call November 8, 2022 8:30 AM ET Company Participants Dave Crawford - VP of IR Ken Reali - CEO Mark Singleton - SVP and CFO Conference Call Participants Chase Knickerbocker - Craig-Hallum Capital Group Caitlin Cronin - Canaccord Genuity Drew Ranieri - Morgan Stanley Philip Coover - Goldman Sachs Rohin Patel - JPMorgan Operator Good day, and welcome to Bioventus Inc. Third Quarter 2022 Earnings Conference Call. All participants will be in a listen-only mode.

Bioventus Inc. (BVS) Q3 2022 Earnings Call Transcript

Los Angeles, California--(Newsfile Corp. - November 11, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Bioventus Inc. ("Bioventus" or "the Company") (NASDAQ: BVS) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION NOTICE: The Schall Law Firm Announces It Is Investigating Claims Against Bioventus Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $BVS #BVS--The Schall Law Firm Announces it is Investigating Claims Against Bioventus Inc. and Encourages Investors with Losses to Contact the Firm

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Bioventus Inc. and Encourages Investors with Losses to Contact the Firm

The company's reduced guidance concerned investors.

Why Shares of Bioventus Fell 14% on Wednesday

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Bioventus Inc. and Encourages Investors with Losses to Contact the Firm

DURHAM, N.C., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the three and nine months ended October 1, 2022.

Bioventus Reports Third Quarter Results; Updates Full-Year 2022 Financial Guidance

DURHAM, N.C., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2022 before the market opens on Tuesday, November 8, 2022. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update.

Bioventus to Report Third Quarter of Fiscal Year 2022 Financial Results on November 8, 2022

Full Launch of BoneScalpel® Access™ at NASS Full Launch of BoneScalpel® Access™ at NASS

Bioventus to Showcase Full Orthobiologics and Ultrasonic Portfolio at NASS in Chicago

Bioventus came in with another set of strong numbers in Q2. We reiterate the buy thesis on BVS and note there are numerous idiosyncratic risk premia on offer.

News for Bioventus Stock (BVS)